(Q38941704)

7 September 2017

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling (English)

1 reference

7 September 2017

1 reference

13

Chris Sander

1 reference

7 September 2017

Nikolaus Schultz

8

0 references

author name string

Jackie Wanjala

1

1 reference

7 September 2017

Barry S Taylor

2

1 reference

7 September 2017

Caren Chapinski

3

1 reference

7 September 2017

Haley Hieronymus

4

1 reference

7 September 2017

John Wongvipat

5

1 reference

7 September 2017

Yu Chen

6

1 reference

7 September 2017

Gouri J Nanjangud

7

1 reference

7 September 2017

Yingqiu Xie

9

1 reference

7 September 2017

Shenji Liu

10

1 reference

7 September 2017

Wenfu Lu

11

1 reference

7 September 2017

Qing Yang

12

1 reference

7 September 2017

Zhenbang Chen

14

1 reference

7 September 2017

Charles L Sawyers

15

1 reference

7 September 2017

Brett S Carver

16

1 reference

7 September 2017

7 November 2014

1 reference

Molecular Cancer Therapeutics

7 September 2017

1 reference

7 September 2017

14

1 reference

7 September 2017

1

1 reference

7 September 2017

278-288

1 reference

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

7 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

The mutational landscape of lethal castration-resistant prostate cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Efficacy of c-Met inhibitor for advanced prostate cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Integrative genomic profiling of human prostate cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Pten dose dictates cancer progression in the prostate

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

c-met proto-oncogene expression in benign and malignant human prostate tissues

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297258

Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer

2 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25381262

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25381262

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1535-7163.MCT-14-0542-T

1 reference

release_epespluagndyraufneznvjv4ce

7 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/epespluagndyraufneznvjv4ce

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

7 September 2017

PubMed publication ID

25381262

1 reference